RxDoctor Payments Data

Thomas Schreiber, MD

Family Medicine · Dubuque, IANPI 1659325694

Payments from drug & device makers

$1,429in general payments, 2019–2025

Across 70 payments — averaging $20.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$291
  • Pfizer$247
  • AbbVie$176
  • Novo Nordisk$103
  • Lilly USA, LLC$103
  • Exact Sciences$76
  • plus $433 from 14 others

What the payments were for

  • Food & beverage$1,24987%
  • Education$18013%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,429 in reported general payments places this provider in the 85th percentile of 1,357 family medicine providers in Iowa.

See all family medicine providers in Iowa

Medicare billing

Part B allowed, 2024
$134,536
Medicare patients
290
Services billed
6,198

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban125$87,880
JardianceEmpagliflozin99$48,965
XareltoRivaroxaban63$44,867
OzempicSemaglutide31$34,650
JanuviaSitagliptin Phosphate68$24,958
FarxigaDapagliflozin Propanediol33$22,369
MyrbetriqMirabegron55$14,997
Arnuity ElliptaFluticasone Furoate39$13,257
Fluticasone-SalmeterolFluticasone Propion/Salmeterol38$6,059
SavellaMilnacipran Hcl12$5,752
Potassium Chloride286$5,192
Atorvastatin Calcium529$4,277
Omeprazole463$4,212
Duloxetine Hcl196$4,067
DuleraMometasone/Formoterol11$3,792

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$247$87,880125 claims
Boehringer IngelheimJardiance$26$48,96599 claims
Johnson & JohnsonXarelto$13$44,86763 claims
Novo NordiskOzempic$103$34,65031 claims
AstraZenecaFarxiga$67$22,36933 claims
Astellas Pharma US IncMyrbetriq$291$14,99755 claims
GSKArnuity Ellipta$36$13,25739 claims
AbbVieSavella$176$5,75212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,357 family medicine providers in Iowa.

Other family medicine in Dubuque

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →